Welcome to our dedicated page for Apollomics Warrant news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on Apollomics Warrant stock.
Apollomics Inc is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies that can be combined with other treatments to target the immune system and molecular pathways for cancer treatment. Their lead programs, vebreltinib (APL-101) and uproleselan (APL-106), show promising results in treating various cancers.
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
FAQ
What is the current stock price of Apollomics Warrant (APLMW)?
What is the market cap of Apollomics Warrant (APLMW)?
What is Apollomics Inc focused on?
What are Apollomics Inc lead programs?
What is vebreltinib (APL-101) used for?
What is uproleselan (APL-106)?
How effective is vebreltinib in treating different tumor types?
What do Phase 2 and 2/3 trials demonstrate about vebreltinib?
How can I contact Apollomics Inc for Investor Relations?
How can I contact Apollomics Inc for Media Relations?
